Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Chemotherapy Drug Shows Promise in Treating Everyday Allergies
Disease Discoveries

Chemotherapy Drug Shows Promise in Treating Everyday Allergies

By Will DossFeb 20, 2018
Share
Facebook Twitter Email
Food allergens can induce cells like this to release substances that can cause a life-threatening allergic reaction, but ibrutinib might be able to interrupt that process.

A drug originally designed for chemotherapy successfully suppressed allergic responses to food allergens, according to a Northwestern Medicine study published in the Journal of Allergy and Clinical Immunology.

The drug, ibrutinib, interrupted the process that causes the body’s cells to react to food allergens such as peanuts or shellfish, showing potential for reducing the severity and risk of allergic reactions, according to lead author Melanie Dispenza, MD, PhD, third-year fellow in the Allergy and Immunology Fellowship Program.

“This drug is reasonably safe, and it effectively blocks allergic responses in cells,” said Bruce Bochner, MD, the Samuel M. Feinberg Professor of Medicine in the Division of Allergy and Immunology, who was senior author of the study.

Ibrutinib works by blocking Bruton’s tyrosine kinase (BTK), an enzyme important to the growth of B-cells, which makes it a prime therapeutic target in treating B-cell lymphomas. BTK also plays a key part in the body’s allergic response.

picture-bochner-bruce
Bruce Bochner, MD, the Samuel M. Feinberg Professor of Medicine in the Division of Allergy and Immunology, was the senior author of the study published in the Journal of Allergy and Clinical Immunology.

A previous Northwestern Medicine study, also with Bochner as senior author, showed ibrutinib reduced allergic responses to an airborne allergen skin prick test, but the study had limitations: the study population was two people with allergies who were taking the drug to treat cancer — so testing their allergic reaction was only a secondary focus. However, it showed that what Bochner and others had seen during allergic reactions in the laboratory might also be happening in people.

“This set the stage for what we really wanted to do: give ibrutinib to allergic adults who had normal immune systems,” Bochner said.

In the current study, Dispenza, Bochner and their colleagues recruited patients with peanut and tree nut allergies, measured their baseline reaction to a food skin prick test and then gave them a seven-day course of ibrutinib. After two days, participants had an average 77 percent reduction the size of their skin test reaction, indicating a successful suppression of their allergic response.

After suspending the medication, most participants were back to their baseline skin test reactivity within a week, according to the study.

While patients with peanut allergies may not be able to simply take ibrutinib and begin eating peanut butter, for example, there are a number of applications where it could be useful, including to give a patient a critically needed medication to which they are allergic, according to Bochner.

“It could also be used to make patients less reactive to a food, so we can retrain their immune system to recognize it as a friend rather than a foe, or to make allergy shots safer,” said Bochner, who is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

In addition, a drug like ibrutinib has the potential to be an improvement on commonly available allergy medications such as antihistamines, according to Dispenza.

Melanie Dispenza shoot. Chicago IL. February 13, 2018. Photo by Andrew Collings.
Melanie Dispenza, MD, PhD, third-year fellow in the Allergy and Immunology Training Program, was the lead author of the study.

“Histamine is just one of the mediators that can cause anaphylaxis,” Dispenza said. “An antihistamine cannot prevent systemic anaphylaxis, but a BTK blocker can prevent release of many mediators, not just histamine.”

Next, the investigators plan to conduct a stepped food challenge: an experiment where participants — with or without pretreatment with the BTK inhibitor — ingest small amounts of allergen such as peanut protein. The amount of allergen ingested by patients is slowly increased until they have a reaction or are able to ingest an entire serving of the allergen. This would be the most realistic experiment yet, and if positive, would represent an exciting milestone for the field, according to Dispenza.

“We’re hoping to see no reaction to these foods when taking ibrutinib, but at least with this protocol there should be a sizable improvement in how much they can eat before they react,” Dispenza said. “We are now finally getting to the heart of a currently unsolvable problem; we’re finding out if we can actually prevent anaphylactic shock.”

This study was funded in part by a 2016 Dixon Translational Innovation Award through the Northwestern University Clinical and Translational Sciences Institute and Northwestern Memorial Foundation, and the Northwestern University Allergy Immunology Research Program (NUAIR) as well as T32 grant AI083216 and K23 grant AI100995 from the National Institute of Allergy and Infectious Diseases.

Allergy & Immunology Cancer Research Residents and Fellows
Share. Facebook Twitter Email

Related Posts

Dissolving Implantable Device Relieves Pain Without Drugs

Jun 30, 2022

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Comments are closed.

Latest News

Physician Assistant Students Embrace ‘Shades of Purple’

Jul 1, 2022

Dissolving Implantable Device Relieves Pain Without Drugs

Jun 30, 2022

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.